Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 547 participants.

Also called NCT01193218

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 547 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01193218
Other papers using this trial's data
  • Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study Advances in therapy, 2015-04 DOI, PubMed 25845768

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01193218. Randomized; double masking; primary purpose treatment. Start 2010-09 (registry gives no type); primary completion 2012-06 (actual). Results posted on 2014-06-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Placebo (low dose)
Intervention (Drug)
Placebo (low dose)
Intervention (Drug)
Placebo (mid dose)
Intervention (Drug)
Placebo (high dose)
Intervention (Drug)
BI 10773
Intervention (Drug)
Placebo (mid dose)
Intervention (Drug)
Placebo (high dose)
Intervention (Drug)
Placebo (high dose)
Intervention (Drug)
BI 10773
Intervention (Drug)
BI 10773
Intervention (Drug)
Placebo (mid dose)
Intervention (Drug)
Placebo (high dose)
Intervention (Drug)
Placebo (low dose)
Intervention (Drug)
Placebo (low dose)
Intervention (Drug)
BI 10773
Intervention (Drug)
Placebo (mid dose)
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01193218
Content hash
e612e3321550c6c725997ad5e5d572eccd79cb691351e84dbe4af129ad9975e6